This formulation, consisting of 50 nm liposomes with 0.7% CD38-targeting peptide density with an EG6 linker and an oligolysine sequence length of three, achieved 45% higher accumulation and fivefold higher tumor cell uptake when compared to nontargeted nanoparticles; twofold higher accumulation and tenfold higher uptake when compared to free doxorubicin; and the greatest efficacy in reducing tumor growth of all groups without showing any detectable signs of systemic toxicity. Here, CD38 is linked to neoplasm.